Skip to main content
Cardiovascular Diabetology logoLink to Cardiovascular Diabetology
. 2024 Feb 20;23:74. doi: 10.1186/s12933-024-02170-w

Correction: Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes

Monica Gamez 1,, Hesham E Elhegni 1, Sarah Fawaz 1, Kwan Ho Ho 2, Neill W Campbell 2, David A Copland 3, Karen L Onions 1, Matthew J Butler 1, Elizabeth J Wasson 1, Michael Crompton 1, Raina D Ramnath 1, Yan Qiu 1, Yu Yamaguchi 4, Kenton P Arkill 5, David O Bates 5, Jeremy E Turnbull 6, Olga V Zubkova 7, Gavin I Welsh 1, Denize Atan 3,8, Simon C Satchell 1, Rebecca R Foster 1
PMCID: PMC10880331  PMID: 38378538

Following publication of the original article [1], the author noticed the error in Discussion section.

In the last paragraph under Discussion section, the sentence “The heterogenous nature of oligo-/polysaccharide derivatives such as PG545 also results in batch variations, further complicating FDA approval” is incorrect. In this text, PG545 should be replaced with SST0001 and should read “The heterogenous nature of oligo-/polysaccharide derivatives such as SST0001 also results in batch variations, further complicating FDA approval”.

Footnotes

The online version of the original article can be found at 10.1186/s12933-024-02133-1.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Gamez M, Elhegni HE, Fawaz S et al. Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes. Cardiovasc Diabetol. 2024;23:50. 10.1186/s12933-024-02133-1. [DOI] [PMC free article] [PubMed]

Articles from Cardiovascular Diabetology are provided here courtesy of BMC

RESOURCES